Cost-effectiveness analysis of afatinib vs gefitinib in EGFR-Mutated population with advanced non-small-cell lung cancer

被引：0
|
作者：
Chouaid, Christos
De Pouvourville, Gerard
Laura, Luciani
机构：
来源：
EUROPEAN RESPIRATORY JOURNAL | 2017年 / 50卷
关键词：
D O I：
10.1183/1393003.congress-2017.PA2794
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA2794
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
    Wu, Yi-Long
    Tsuboi, Masahiro
    He, Jie
    John, Thomas
    Grohe, Christian
    Majem, Margarita
    Goldman, Jonathan W.
    Laktionov, Konstantin
    Kim, Sang-We
    Kato, Terufumi
    Vu, Huu-Vinh
    Lu, Shun
    Lee, Kye-Young
    Akewanlop, Charuwan
    Yu, Chong-Jen
    de Marinis, Filippo
    Bonanno, Laura
    Domine, Manuel
    Shepherd, Frances A.
    Zeng, Lingmin
    Hodge, Rachel
    Atasoy, Ajlan
    Rukazenkov, Yuri
    Herbst, Roy S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18): : 1711 - 1723
  • [22] Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer
    Aguiar, Pedro N., Jr.
    Haaland, Benjamin
    Park, Wungki
    Tan, Pui San
    del Giglio, Auro
    Lopes, Gilberto de Lima, Jr.
    JAMA ONCOLOGY, 2018, 4 (08) : 1080 - 1084
  • [23] Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States
    Huo, Gengwei
    Song, Ying
    Liu, Wenjie
    Cao, Xuchen
    Chen, Peng
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [24] Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
    Maemondo, Makoto
    Inoue, Akira
    Kobayashi, Kunihiko
    Sugawara, Shunichi
    Oizumi, Satoshi
    Isobe, Hiroshi
    Gemma, Akihiko
    Harada, Masao
    Yoshizawa, Hirohisa
    Kinoshita, Ichiro
    Fujita, Yuka
    Okinaga, Shoji
    Hirano, Haruto
    Yoshimori, Kozo
    Harada, Toshiyuki
    Ogura, Takashi
    Ando, Masahiro
    Miyazawa, Hitoshi
    Tanaka, Tomoaki
    Saijo, Yasuo
    Hagiwara, Koichi
    Morita, Satoshi
    Nukiwa, Toshihiro
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (25): : 2380 - 2388
  • [25] COST-EFFECTIVENESS OF DACOMITINIB VS. GEFITINIB AS FIRST-LINE TREATMENT FOR EGFR MUTATION POSITIVE ADVANCED NON-SMALL-CELL LUNG CANCER IN CHINA
    Yu, Y.
    Luan, L.
    Zhu, F.
    Dong, P.
    Li, L.
    Lin, Y.
    Lu, S.
    VALUE IN HEALTH, 2019, 22 : S467 - S468
  • [26] Cost-effectiveness of osimertinib versus placebo in resected EGFR-mutated non-small cell lung cancer in China
    Zhou, Xiwen
    Du, Jianting
    Xu, Guobing
    Chen, Chun
    Zheng, Bin
    Chen, Jiahe
    CANCER MEDICINE, 2022, 11 (23): : 4449 - 4456
  • [27] Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada
    Kim, Yong-Jin
    Oremus, Mark
    Chen, Helen H.
    McFarlane, Thomas
    Fearon, Danielle
    Horton, Susan
    PHARMACOECONOMICS, 2021, 39 (05) : 537 - 548
  • [28] Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada
    Yong-Jin Kim
    Mark Oremus
    Helen H. Chen
    Thomas McFarlane
    Danielle Fearon
    Susan Horton
    PharmacoEconomics, 2021, 39 : 537 - 548
  • [29] Non-small-cell lung cancer: how to manage EGFR-mutated disease
    Pecci, Federica
    Cantini, Luca
    Metro, Giulio
    Ricciuti, Biagio
    Lamberti, Giuseppe
    Farooqi, Ammad Ahmad
    Berardi, Rossana
    DRUGS IN CONTEXT, 2022, 11
  • [30] Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China
    Guan, Haijing
    Liu, Gordon
    Xie, Feng
    Sheng, Yanan
    Shi, Luwen
    CLINICAL THERAPEUTICS, 2019, 41 (11) : 2308 - 2320
12345